Please enable Javascript
Elizabeth Wulff-Burchfield, MD
Elizabeth Wulff-Burchfield, MD, University of Kansas Medical Center
Articles by Elizabeth Wulff-Burchfield, MD
Redefining Quality of Life: The Future of Patient-Reported Outcomes
Elizabeth Wulff-Burchfield, MD
Prostate Cancer
|
May 15, 2025
Drs. Wulff-Burchfield and Beckermann offer perspective on how patient-driven science is shaping QOL measurement.
View More
Reframing Cancer Treatment: Trust, Transparency, and the Human Side of Care
Elizabeth Wulff-Burchfield, MD
Prostate Cancer
|
May 15, 2025
Drs. Wulff-Burchfield and Beckermann share how they help GU patients make informed, personalized treatment decisions.
View More
The Art of the Consult: Goals, Trade-offs, and Treatment in GU Oncology
Elizabeth Wulff-Burchfield, MD
Prostate Cancer
|
May 15, 2025
Drs. Wulff-Burchfield and Beckermann discuss how GU oncologists can build trust and deepen patient connections.
View More
Expert Panel Shares Forward-Looking Thoughts on RCC Treatment, Clinical Trials
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel shared their excitement for the road ahead in kidney cancer.
View More
RCC Panel Discusses Treatment Response, Dosing, Patient Management, and More
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
View More
LITESPARK-005 Study Results and Thoughts on Second-Line RCC Treatment
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
View More
CheckMate 67T Offers a Look at a Different Treatment Route of Administration
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel discussed the impact of a subcutaneous formulation of nivolumab.
View More
Panel Discusses Other RCC Treatment Options: Radiation Techniques, Surgery, and More
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
View More
CheckMate 9ER: Frontline Nivolumab/Cabozantinib in RCC Patients With Metastases, QOL Considerations
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
View More
RCC Panel Reacts to Long-Term Follow-Up From CheckMate 214
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
View More
ASCO GU Data Updates: KEYNOTE-564 and CheckMate 914
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
View More